Informations générales (source: ClinicalTrials.gov)
Cognitive Markers of Response to Treatment in Resistant Depression (DEP-ICOR)
Observational
Centre Hospitalier Universitaire de Nice (Voir sur ClinicalTrials)
janvier 2015
juin 2017
29 juin 2024
Patients with depression are frequently treatment resistant. Clinical manifestations of
depression are various, but cognitive dysfunctions are commonly present. Many factors are
involved in treatment resistance. As no biological marker is available, clinical markers
could be considered in predicting response to antidepressive treatment.
The aim of this study is to investigate the relation between the cognitive changes and
the remission of depressive symptoms in patients with recurrent depression (Stage 2 of
Thase and Rush classification).
To explore the dynamics of cognitive dimension associated to clinical and functional
remission, the investigators will observe neurocognitive functioning before and after
introducing a new antidepressive therapy.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hopital Pasteur - 06000 - Nice - France | Nelly Darmon | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patients will be aged from 40 to 70, with a major depressive episode diagnosis with
a 2 stage degree of resistance.
- Patients will be aged from 40 to 70, with a major depressive episode diagnosis with
a 2 stage degree of resistance.
- Patients with major depressive episode during more of 12 months
- Alzheimer dementia or related disease (CIM 10)
- Score Hamilton Depression Rating Scale (HDRS) < 18